GlassScriptPhysician profile
Michael A Eller
NPI 1952636201
$5,031.40
in general payments reported to CMS, 2019-2025
37 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.36 · 2022: $1,384 · 2023: $1,151 · 2024: $1,152 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,563.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,592.87 | 2022-2025 | |
| Lilly USA, LLC | $441.59 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $441.29 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $368.07 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $349.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $178.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.28 | 2021-2025 | Breztri, Farxiga |
| Alkermes, INC. | $128.27 | 2022-2023 | Vivitrol |
| Amgen INC. | $124.77 | 2023-2025 | Repatha, Otezla, Evenity |
| Amneal Pharmaceuticals LLC | $119.17 | 2023-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $119.01 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.79 | 2021-2024 | Jardiance, Synjardy, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $86.03 | 2023-2025 | Trintellix |
| Exact Sciences Corporation | $71.60 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $69.91 | 2023-2024 | Accrufer |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.91 | 2023-2025 | Camzyos, Eliquis |
| Dexcom, INC. | $65.01 | 2022-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $57.20 | 2025 | Auvelity |
| Halozyme INC | $45.10 | 2023 | |
| Boston Scientific Corporation | $40.23 | 2024-2025 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.78 | 2025 | Caplyta |
| Abbott Laboratories | $35.03 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.92 | 2025 | Xifaxan |
| Acella Pharmaceuticals, LLC | $31.12 | 2025 | NP Thyroid 60 |
| Neos Therapeutics, LP | $30.07 | 2022-2023 | Adzenys Xr-Odt |
| Paratek Pharmaceuticals, INC. | $28.64 | 2024-2025 | Nuzyra |
| Insulet Corporation | $25.15 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $24.54 | 2024 | Nexletol |
| Astellas Pharma US INC | $23.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.57 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $21.09 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.92 | 2025 | Voquezna |
| Ars Pharmaceuticals Operations, INC. | $19.32 | 2025 | Neffy |
| Antares Pharma, INC. | $16.46 | 2024 | Xyosted |
| Corium, LLC | $15.71 | 2022 | |
| Medtronic, INC. | $15.12 | 2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $14.16 | 2024 | Varivax, Gardasil, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Eller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.